Court Sets Aside Viatris, Innovata HIV Drug Deals

A South African high court ruled the health department should reconsider the R12.2bn tenofovir-lamivudine-dolutegravir tender after both firms' licences were found expired.

Updated on Nov. 11, 2026 in Healthcare

Isometric editorial illustration of unlabeled white blister strips and an amber vial on a pale grey plinth, with a dry horizon behind, evoking a disrupted HIV medicine supply.
South Africa's high court on October 20, 2026 set aside Viatris and Innovata's R12.2bn HIV drug contracts after finding their manufacturing licences had expired, ordering the health department to reconsider the tender. AI Illustration. Upload story photo >

On 20 October 2026, a South African high court set aside the tenofovir-lamivudine-dolutegravir (TLD) contracts held by Viatris and Innovata, part of a R15.5bn Aids drug tender. Viatris and Innovata have since filed papers setting out grounds for appeal.

Why it matters

The court found both firms should have been disqualified because their manufacturing licences had expired when the bid window closed, and that Cipla Medpro had been unfairly excluded. The ruling could reshape how a major share of South Africa's HIV treatment supply is awarded.

The disputed TLD contracts are worth R12.2bn of the R15.5bn total Aids drug tender, with Viatris holding about R1.67bn and Innovata about R1.575bn. The health department has 120 days to reconsider eligible bidders and revise the contract split, and it is not yet clear how the appeals will affect that timeline.

The players

Viatris

A global pharmaceutical company that held one of the disputed TLD supply contracts and is now seeking leave to appeal the court's ruling.

Innovata

A pharmaceutical supplier that held a TLD contract set aside by the court and has challenged the judge's findings and the directive on its independence from Barrs.

Cipla Medpro

The South African arm of the Indian drugmaker Cipla, whose application led to the court ruling that it had been unfairly excluded from the tender.

The details

The court upheld an application by Cipla Medpro, finding that Viatris and Innovata's manufacturing licences had lapsed when the bid window closed. Viatris said it was awaiting renewal of its manufacturing licence from SAHPRA and held a valid import licence at the time, while Innovata has challenged the judge's findings and the directive to investigate its independence from Barrs.

Timeline

  1. 20 October 2026: High court set aside the Viatris and Innovata TLD contracts.

  2. Monday before 11 November 2026: Viatris filed papers setting out grounds for a potential appeal.

  3. Week before 11 November 2026: Innovata filed papers challenging the judge's findings.

  4. 120 days after 20 October 2026: Deadline for the health department to reconsider the tender.

Healthcare Procurement

The ruling places South Africa's public antiretroviral tender process under scrutiny over whether licence status was properly verified at bid close. It reflects how the country's large public HIV treatment purchases depend on supplier compliance checks.

The outcome determines which suppliers can provide the TLD regimen used in South Africa's public HIV treatment programme. Any delay in reconsidering the tender could affect the availability and pricing of these medicines.

The takeaway

Licence compliance at bid close can decide a major public health contract, so suppliers and procurers alike should verify it carefully. Watch the appeal outcome and the health department's revised tender.

What happens next

The health department must reconsider the tender within 120 days of 20 October 2026, and the appeals filed by Viatris and Innovata are pending.

Further reading

For broader context on public health supply, see Healthcare coverage of South Africa.